Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.68 |
| ▸ | RARB | P10826 | 6/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | RARA | P10276 | 1/20 | 0.66 |
| ▸ | MTOR | P42345 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.59 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.58 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.58 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.58 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.58 |
| ▸ | DPP4 | P27487 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2402134 | 1.00 | HDAC1 (0.68) | HDAC1RARBMAPTMEN1ALDH1A1 | |
| SCHEMBL1980515 | 0.98 | RARB (0.65) | HDAC1RARBMAPTMEN1ALDH1A1 | |
| SCHEMBL1982703 | 0.94 | HDAC8 (0.67) | HDAC1RARBMAPTMEN1ALDH1A1 | |
| SCHEMBL28873230 | 0.94 | RARB (0.72) | HDAC1RARBMAPTMEN1ALDH1A1 | |
| SCHEMBL9472454 | 0.94 | RARB (0.72) | HDAC1RARBMAPTMEN1ALDH1A1 | |
| SCHEMBL30053056 | 0.94 | RARB (0.72) | HDAC1RARBMAPTMEN1ALDH1A1 | |
| SCHEMBL15583704 | 0.94 | RARB (0.72) | HDAC1RARBMAPTMEN1ALDH1A1 | |
| SCHEMBL371605 | 0.91 | RARB (0.71) | HDAC1RARBMAPTMEN1ALDH1A1 | |
| SCHEMBL1926270 | 0.89 | HDAC1 (0.64) | HDAC1RARBALDH1A1HDAC8 | |
| SCHEMBL8894364 | 0.89 | HDAC1 (0.64) | HDAC1RARBALDH1A1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1868991-B1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8178528-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178528-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178528-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100160406-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20100160406-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20100160406-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2010-06-24 | — | — | US | disclosed |
| EP-1868991-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006107661-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160406-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | HDAC1 566/4885RARB 2301/4885MAPT 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.